Healthcare Unusual Volume: Palatin Technologies (NYSEMKT:PTN), AVEO Pharmaceuticals (NASDAQ:AVEO), Aastrom Biosciences (NASDAQ:ASTM), Merrimack Pharmaceuticals (NASDAQ:MACK)

Palatin Technologies (NYSE:PTN) major shareholder Bvf Partners L. P/Il sold 540,181 shares of Palatin Technologies stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $1.14, for a total transaction of $615,806.34. Palatin Technologies, Inc. (NYSEMKT:PTN) stock performance was 17.07% in last session and finished the day at $1.44. Traded volume was 3.33 million shares in the last session and the average volume of the stock remained 716,760.00 shares. The beta of the stock remained 1.83. Palatin Technologies, Inc. (NYSEMKT:PTN) insider ownership is 1.19%.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (NASDAQ:BIIB). AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) rose 7.19% to $1.79 Friday on volume of 2.97 million shares. The intra-day range of the stock was $1.71 – $1.88. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has a market capitalization of 92.28 million.

Aastrom Biosciences (NASDAQ:ASTM) stock had its “neutral” rating reiterated by Zacks in a note issued to investors on Friday, Analyst Ratings Network reports. They currently have a $5.00 price target on the stock. Zacks‘s target price would suggest a potential upside of 38.12% from the stock’s previous close. Aastrom Biosciences Inc. (NASDAQ:ASTM)’s stock on March 21, 2014 reported a higher of 30.58% to the closing price of $6.49. Its fifty two weeks range is $3.14 – $24.40. The total market capitalization recorded 19.74 million. The overall volume in the last trading session was 5.39 million shares. In its share capital, Aastrom Biosciences Inc. (NASDAQ:ASTM) has 3.04 million outstanding shares.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) on Feb. 27 announced its fourth quarter and full year 2013 financial results. On Friday, shares of Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) dropped -1.30% to close the day at $5.32. Company return on investment (ROI) is -176.90% and its monthly performance is recorded as 8.79%. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) quarterly revenue growth is 6.19%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone